Recent advances in understanding the cellular and molecular mechanisms of atopy have shed light on potential targets for the development of new therapies for allergic diseases. In this issue of the JCI, Seshasayee et al. provide direct in vivo evidence that OX40 has critical roles in allergic inflammation mediated by thymic stromal lymphopoietin (TSLP) (see the related article beginning on page 3868). Blockade of interactions between OX40 on Th2 cells and OX40 ligand (OX40L) on TSLP-activated DCs using an OX40L-specific monoclonal antibody, inhibited Th2 cell–mediated immune responses in both mouse and nonhuman primate models of allergic inflammation. The results point to potential therapeutic approaches to targeting the cellular and molecular mechanism underlying TSLP-mediated allergic inflammation.

TSLP: bridging the epithelial barrier and type 2 immune responses

Asthma and atopic dermatitis (AD) are inflammatory disorders characterized by the infiltration and accumulation of memory-like Th2 cells and eosinophils (1). In addition to the type 2 inflammatory processes, allergic diseases often involve epithelial cell stress and injury that trigger the release of chemokines and growth factors able to support both chronic inflammatory and remodeling responses. The idea that reduced barrier function of the epithelium and altered innate immunity are fundamental to the origin of these diseases is supported by the recent finding that thymic stromal lymphopoietin (TSLP), an IL-7–like cytokine, plays a key role in allergic inflammation at the interface between epithelial cells and DCs (2). TSLP is highly expressed by keratinocytes in skin lesions of patients with AD (3) and by airway epithelial cells of individuals with asthma (4) and can potentially activate myeloid DCs by upregulating their surface expression of MHC class II, CD54, CD80, CD83, CD86, and DC-lamp (3). Interestingly, TSLP triggers human myeloid DCs to produce a myriad of chemokines that recruit eosinophils and Th2 cells, but it does not trigger them to produce either Th1-polarizing cytokines of the IL-12 family or the proinflammatory cytokines TNF-α, IL-1β, and IL-6, resulting in a microenvironment permissive for type 2 inflammatory responses (5). TSLP-activated DCs can induce naïve T cells to differentiate into inflammatory Th2 cells producing the classical Th2 cytokines IL-4, IL-5, and IL-13, as well as a large amount of TNF-α but little or no IL-10 (6). Moreover, only TSLP-activated DCs can induce in vitro, allergen-specific Th2 memory cells to undergo homeostatic expansion and further Th2 polarization, and to mediate recall responses (7). In support of the findings in humans, mice with conditional overexpression of TSLP in keratinocytes were found to have an AD-like phenotype characterized by scaling lesions accompanied by infiltration of Th2 CD4+ cells in skin and elevated serum IgE level (8).
That overexpression of TSLP in mice lack (10). Indeed, human TSLP, synergistically effector cells of the innate immune system or cutaneous allergic inflammation, sug during allergic inflammation controlling the fate of CD4 T cells (+), Th2 effector cells (IL-4, IL-5, IL-13, and TNF-α) initiate allergic inflammation by triggering OX40 on the T cells, it contributes to prolonging the cognate T cell–DC interaction (7). Blockade of OX40-OX40L interactions resulted in arrest at the G0 phase of the cell cycle and limited the proliferation of Th2 memory cells induced by autologous TSLP-activated DCs (7). These data identify plausible explanations for the importance of OX40L during TSLP-mediated allergic inflammation, highlighting its roles in the induction of inflammatory Th2 cells and the maintenance of the Th2 memory cell pool.

In allergen-induced models of allergy, mice lacking OX40 or OX40L exhibit markedly impaired reactivation of Th2 memory cells and Th2 responses, as well as diminished lung inflammation (18, 19). Building on earlier findings in humans and mice (discussed above), Seshasayee et al. have further demonstrated the role of OX40L in TSLP-induced allergic inflammation in the skin of mice and in the lung of mice and nonhuman primates (20). They generated a chimeric hamster-mouse mAb and a fully human mAb specific for mouse and human OX40L, respectively. These invaluable OX40L-specific mAbs proved to be efficacious in inhibiting antigen-driven Th2 inflammation in mouse and nonhuman primate models of asthma. Administration of their OX40L-specific mAbs resulted in substantial reductions in the amount of Th2 cytokines and antigen-specific IgE and IgG1, as well as the loss of infiltrating eosinophils and CD4+ effector/memory T cells. These results demonstrated that in vivo, OX40L is a dominant mediator of TSLP-induced allergic inflam-
mation in the lung and skin of mice. Most importantly, the study by Seshasayee et al. has provided direct evidence that OX40L is required to elicit disease in antigen-driven models of asthma in mice and, in particular, in antigen-driven models of asthma in nonhuman primates, i.e., rhesus monkeys. They further showed that the effects of their mAbs were mediated by blocking OX40-OX40L interactions and depleting OX40L DCs. Interestingly, the treatments resulted in only a moderate reduction in the primary effector Th2 inflammatory response, but a marked decrease in reactivation and infiltration of memory CD4+ T cells, production of Th2 cytokines, and antigen-specific serum IgE levels was observed during the recall response to antigen. These results demonstrated that the maintenance and reactivation of Th2 memory cells by OX40L-expressing DCs contributes to the pathogenesis of TSLP-mediated allergic inflammation. In mouse and nonhuman primate models of asthma, the therapeutic efficacy of targeting the regulation and function of pathogenic Th2 memory cells, using OX40L-specific mAbs — as shown in the study by Seshasayee et al. — points to a new therapeutic approach for the prevention and treatment of human allergic diseases.

Future perspectives

Studies using mice lacking OX40 or OX40L have demonstrated that the OX40 signaling pathway plays important roles in controlling the fate and functions of CD4+ T cell not only in TSLP-mediated allergic diseases but also in other models of inflammatory immune disorders, including EAE and animal models of inflammatory bowel disease and graft-versus-host disease (16). These observations suggest that inhibitors targeting OX40 and OX40L in vivo might provide new therapeutic strategies for several inflammatory immunological disorders.

Indeed, two different OX40-specific therapeutic interventions have been successful in the treatment of animals with EAE (21, 22). An OX40-specific immunotoxin that depletes autoreactive OX40+ T cells (21) and an OX40L-binding agent that blocks OX40-OX40L interactions (22) have both been reported to successfully reduce the clinical symptoms of EAE in mice. An OX40L-specific mAb has also been employed for the treatment of disease in a mouse model of asthma (22, 23); however, variations in the therapeutic efficacy of this mAb were observed in different strains of mice (16).

Therefore, the efficacy of treatment with OX40L-specific mAbs for human allergic asthma might also vary from individual to individual. Whether the effect of blocking OX40-OX40L interactions results in a reduction in the size of other OX40+ memory T cell pools might need further detailed examinations in vivo.

The unexpected findings that point to a role for TSLP in allergic inflammation provide insights for designing new therapeutic approaches for the treatment of human atopic diseases. The finding that TSLP is highly expressed by keratinocytes in the skin and in airway epithelial cells during allergic inflammation raises the question of how expression of TSLP is triggered in these cells. Whether allergen exposure or virus infection can induce TSLP overexpression in the inflammatory tissues remains unclear. The expression of retinoid X receptor (RXR) in keratinocytes might actively suppress TSLP production under normal physiological conditions (24). Further studies on the regulation of this receptor might provide important clues about how allergens or viral infections trigger TSLP production and lead to other therapeutic approaches. Targeting TSLP and the OX40-OX40L interaction can be considered as the first step toward immunological intervention in the treatment of allergic diseases.

Address correspondence to: Yong-Jun Liu or Yui-Hsi Wang, Department of Immunology and Center of Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 178, Houston, Texas 77030, USA. Phone: (713) 563-3203; Fax: (713) 563-3275; E-mail: yliu@mdanderson.org (Y.-J. Liu). Phone: (713) 563-3306; Fax: (713) 563-3275; E-mail: yuwang@mdanderson.org (Y.-H. Wang).
